Testing teplizumab vs. ATG to delay type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial compares two medicines, teplizumab and ATG, to see if they can delay or prevent type 1 diabetes from progressing to needing insulin. It is for people ages 4 to 35 who have early signs of diabetes (stage 2) and specific autoantibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 4 to 34 years old
- You have at least two diabetes-related autoantibodies in your blood (certain combinations count, ask your doctor)
- Your blood sugar tests show early, pre-symptomatic type 1 diabetes (stage 2) — confirmed within the last 100 days
- You are generally healthy and free of other untreated medical conditions
- You have not been treated with teplizumab or ATG before
- You are not pregnant, breastfeeding, or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
This study follows children who are at genetic risk for type 1 diabetes or have early immune signs (autoantibodies) but do not yet need insulin. It provides extra checkups and information to catch the disease early and help families understand their child's risk.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This trial tests whether the drug golimumab (an immune-modulating medicine) can delay or prevent type 1 diabetes in people who have early signs of autoimmunity but still have normal blood sugar. It compares golimumab to a placebo (a dummy treatment) to see if it can protect the insulin-making cells in the pancreas.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.